Shiina H, Igawa M, Shigeno K, Wada Y, Yoneda T, Yagi H, Shirakawa R, Nagasaki M
Department of Urology, Shimane Medical University, Izumo, Japan.
Oncology. 1997 Nov-Dec;54(6):482-9. doi: 10.1159/000227607.
To elucidate the biological significance of proliferating cell nuclear antigen (PCNA) and nm23 immunoreactivity in prostatic carcinoma (PC) tissue, both expressions were immunohistochemically analyzed, and the results were compared with the change of the serum testosterone (T) level.
The paraffin-embedded materials obtained from 49 untreated PC and 16 hormonally refractory PC (hr-PC) were used. Of the 49 untreated PC, 35 received luteinizing hormone-releasing hormone (LH-RH) analogue treatment, while 14 received a cisplatin-based chemotherapy. The immunohistochemistry of PCNA and nm23 protein was performed using an anti-PCNA monoclonal antibody (PC-10) and an antihuman nm23 polyclonal antibody (OA-11-890), respectively. The serum T level was measured by means of radioimmunoassay.
In both untreated PC and hr-PC, the immunoreactivity of nm23 protein significantly correlated with the PCNA expression. Both PCNA expression and nm23 protein immunoreactivity were higher in poorly differentiated PC than those observed in well-differentiated PC, while no significant difference in the serum T level was observed between poorly and well-differentiated PCs. On the other hand, both PCNA expression and nm23 protein immunoreactivity were significantly higher in hr-PC than those observed in untreated PC, whereas the serum T level was significantly lower in hr-PC. In 35 PCs treated with LH-RH analogue, no significant difference in both PCNA expression and nm23 protein immunoreactivity was found between those specimens obtained before and at 3 months after the treatment, while a significant reduction of the serum T level was noted at 3 months after the treatment. Similarly, in 14 PCs treated with a cisplatin-based chemotherapy, the same change of PCNA expression and nm23 protein immunoreactivity as observed in LH-RH analogue treatment was found, while no significant difference of the serum T level was found.
These findings appear to indicate that (1) nm23 protein immunoreactivity is interrelated with cellular proliferation in PC tissue and (2) alteration of the serum T level during a short period was not enough to explain the essential change of cellular proliferation of PC tissue, but might reflect other aspects of tumor growth such as apoptosis.
为阐明增殖细胞核抗原(PCNA)和nm23免疫反应性在前列腺癌(PC)组织中的生物学意义,对这两种表达进行免疫组织化学分析,并将结果与血清睾酮(T)水平的变化进行比较。
使用从49例未经治疗的PC和16例激素难治性PC(hr-PC)获取的石蜡包埋材料。在49例未经治疗的PC中,35例接受促黄体生成素释放激素(LH-RH)类似物治疗,14例接受以顺铂为基础的化疗。分别使用抗PCNA单克隆抗体(PC-10)和抗人nm23多克隆抗体(OA-11-890)对PCNA和nm23蛋白进行免疫组织化学检测。通过放射免疫测定法测量血清T水平。
在未经治疗的PC和hr-PC中,nm23蛋白的免疫反应性均与PCNA表达显著相关。低分化PC中的PCNA表达和nm23蛋白免疫反应性均高于高分化PC,而高分化和低分化PC之间的血清T水平无显著差异。另一方面,hr-PC中的PCNA表达和nm23蛋白免疫反应性均显著高于未经治疗的PC,而hr-PC中的血清T水平显著更低。在35例接受LH-RH类似物治疗的PC中,治疗前和治疗后3个月获取的标本之间,PCNA表达和nm23蛋白免疫反应性均无显著差异,而治疗后3个月血清T水平显著降低。同样,在14例接受以顺铂为基础化疗的PC中,发现PCNA表达和nm23蛋白免疫反应性的变化与LH-RH类似物治疗中观察到的相同,而血清T水平无显著差异。
这些发现似乎表明:(1)nm23蛋白免疫反应性与PC组织中的细胞增殖相关;(2)短期内血清T水平的改变不足以解释PC组织细胞增殖的本质变化,但可能反映肿瘤生长的其他方面,如细胞凋亡。